DOPTELET (Swedish Orphan Biovitrum Pty Ltd)
Product name
DOPTELET
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
248 (255 working days)
Active ingredients
avatrombopag maleate
Registration type
NCE/NBE
Indication
DOPTELET is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.
DOPTELET is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.